INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 434m ago
HOUSE PTR33m ago
SEC 13F33m ago
ROBINHOOD CHAIN33m ago
Public company

ONCBeOne Medicines Ltd.

CIK 0001651308

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 42
Max Insider Score50
Connections11with evidence

ONC · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
4
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$313K
880 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Wang XiaodongDirector, Chair, Scientific Advisory Brd · Sep 10, 2026
  • ← Insider ofevidence
    Mooney Elizabeth FisherDirector · Jun 15, 2026
  • ← Insider ofevidence
    Sawyers Charles LazelleDirector · Jun 15, 2026
8
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL
$845K
2,331 sh
Oct 27, 2026
Oct 29, 2026
traded Oct 27, 2026
+2d
SEC FORM 4

Evidence

15
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$2.96M
8,148 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

0
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
403.4K sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

4
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$460K
1,280 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

15
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$1.45M
3,965 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

19
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$2.53M
6,903 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

4
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$512K
1,440 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

8
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$603K
1,681 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

1
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$115K
320 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

1
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$1.14M
31.0K sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

4
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$443K
1,239 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

15
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$1.03M
2,841 sh
Oct 27, 2026Oct 29, 2026
traded Oct 27, 2026
+2dSEC FORM 4

Evidence

20
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$2.51M
7,167 sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

20
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$3.63M
10.4K sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

4
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
403.4K sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

24
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$2.31M
6,558 sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

20
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$2.00M
5,681 sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

21
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$445K
1,260 sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

1
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$1.14M
31.0K sh
Oct 13, 2026Oct 15, 2026
traded Oct 13, 2026
+2dSEC FORM 4

Evidence

21
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$418K
1,115 sh
Sep 30, 2026Oct 2, 2026
traded Sep 30, 2026
+2dSEC FORM 4

Evidence

21
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$271K
738 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

24
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$5.32M
14.5K sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

4
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
403.4K sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

6
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$57K
160 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

3
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$14K
40 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

16
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$1.54M
4,239 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

13
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$749K
2,047 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

13
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$809K
2,241 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

16
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$1.27M
3,499 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

3
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$43K
120 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

1
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$1.14M
31.0K sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

16
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$1.24M
3,419 sh
Sep 28, 2026Sep 30, 2026
traded Sep 28, 2026
+2dSEC FORM 4

Evidence

31
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$2.21M
6,278 sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

7
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
403.4K sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

20
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$408K
1,181 sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

24
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$527K
1,517 sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

31
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$2.30M
6,569 sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

27
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$2.61M
7,492 sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

28
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$599K
1,721 sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

27
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$3.73M
10.7K sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

24
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$983K
2,841 sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

8
WX
Wang XiaodongDirector, Chair, Scientific Advisory Brd
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$1.14M
31.0K sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

23
WX
Wu XiaobinPresident and COO
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$106K
280 sh
Aug 25, 2026Aug 27, 2026
traded Aug 25, 2026
+2dSEC FORM 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
13.8K sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
10.3K sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M—
10.6K sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

3
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$127K
796 sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

7
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$226K
1,058 sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

21
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Open-market sale · 10b5-1 plan
SELL$960K
2,666 sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

0
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Option exercise · 10b5-1 plan
M$158K
812 sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

47
WX
Wu XiaobinPresident and COO
ONCBeOne Medicines Ltd.
Open-market sale
SELL$357K
1,292 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC FORM 4

Evidence

50
WL
Wang LaiPresident, Global Head of R&D
ONCBeOne Medicines Ltd.
Open-market sale
SELL$296K
1,068 sh
Jun 23, 2026Jun 25, 2026
traded Jun 23, 2026
+2dSEC FORM 4

Evidence

50
WL
Wang LaiPresident, Global Head of R&D
ONCBeOne Medicines Ltd.
Open-market sale
SELL$310K
1,169 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

44
LH
Lee Chan HenrySVP, General Counsel
ONCBeOne Medicines Ltd.
Open-market sale
SELL$157K
590 sh
Jun 16, 2026Jun 18, 2026
traded Jun 16, 2026
+2dSEC FORM 4

Evidence

9
WL
Wang LaiPresident, Global Head of R&D
ONCBeOne Medicines Ltd.
Grant or award
A—
118.6K sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

9
MF
Mooney Elizabeth FisherDirector
ONCBeOne Medicines Ltd.
Grant or award
A—
19.0K sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

5
WL
Wang LaiPresident, Global Head of R&D
ONCBeOne Medicines Ltd.
Grant or award
A—
229.8K sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

47
WL
Wang LaiPresident, Global Head of R&D
ONCBeOne Medicines Ltd.
Open-market sale
SELL$197K
756 sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

13
DM
Dugan MargaretDirector
ONCBeOne Medicines Ltd.
Grant or award
A—
19.0K sh
Jun 11, 2026Jun 15, 2026
traded Jun 11, 2026
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Wang LaiPresident, Global Head of R&D · Jun 10, 2026
  • ← Insider ofevidence
    Dugan MargaretDirector · May 27, 2026
  • ← Insider ofevidence
    Riva AlessandroDirector · May 27, 2026
  • ← Insider ofevidence
    Rosenberg AaronChief Financial Officer · Mar 10, 2026
  • ← Insider ofevidence
    Sanders Corazon (Corsee) D.Director · Dec 1, 2025
  • ← Insider ofevidence
    Lee Chan HenrySVP, General Counsel · Nov 14, 2025
  • ← Insider ofevidence
    Wu XiaobinPresident and COO · Nov 14, 2025